Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/06/26	0.7500 €	-0.53%	24,387
16/06/26	0.7540 €	-0.92%	36,427
15/06/26	0.7610 €	-1.04%	45,329
12/06/26	0.7690 €	-0.13%	18,434
11/06/26	0.7700 €	+1.05%	10,393

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7500EUR

Average target price

1.100EUR

Spread / Average Target

+46.67%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 17/06/2026 BST			5-day change	1st Jan Change
0.7500 ^EUR	-0.53%		-3.23%	-21.88%

05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI

Market Cap	205M 236M 189M 178M 333M 22.44B 337M 2.25B 872M 10.97B 887M 868M 37.96B	P/E 2026 *	-5.36x	P/E 2027 *	-3.41x
Enterprise Value	136M 157M 125M 118M 221M 14.88B 223M 1.49B 578M 7.27B 588M 575M 25.17B	EV / Sales 2026 *	18.9x	EV / Sales 2027 *	27.5x
Free-Float	65.65%	Yield 2026 *	-	Yield 2027 *	-

05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio
04-03	Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine	MT
04-02	Transgene and NEC Bio Sign License Agreement for TG4050 Development in Head and Neck Cancer	CI
04-02	Transgene & NEC Bio sign license agreement to prepare next steps of development of TG4050 in head & neck cancer	RE
03-25	Danone, Dassault Systèmes, Orange... stocks to watch today in Paris
03-24	Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Transgene SA, 2025 Earnings Call, Mar 24, 2026
03-24	Transgene SA says myvac platform to initiate phase 1 trial in second indication in 2026	RE
03-24	Ipsos, NRJ Group, Transgene: Stocks to watch tomorrow in Paris
03-24	Transgene reports full-year results and provides operational update
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris

04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
13/10/25	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
18/09/25	Transgene: analysts reiterate their recommendations after results
17/09/25	The day the Fed resumed its rate cuts

Transgene Share Price

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news : Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Course Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

05-26	Transgene : Investor presentation (20260526 Transgene Investor Presentation)	PU
05-26	Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases	GL
05-22	Transgene’s Combined General Meeting of May 22, 2026	GL
05-04	Transgene : Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026	PU
05-04	Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026	GL

05-26	Bourse : Saint-Gobain cède un actif, Thales signe un contrat en Grèce, Kingfisher publie
05-26	Transgene présente des résultats précliniques avec TG-MVA, un nouveau vaccin prophylactique contre la variole du singe (mpox), au Congrès mondial sur les maladies infectieuses
05-26	Petite actu, grosse hausse
05-22	Assemblée Générale Mixte de Transgene du 22 mai 2026
05-22	Transgene : Résultats du vote (17805 RESULTATS DU SCRUTIN)

1 day	-0.53%
1 week	-3.23%
Current month	-10.18%
1 month	-10.61%
3 months	-2.60%
6 months	-21.55%
Current year	-21.88%

1 week	0.75	0.77
1 month	0.75	0.85
Current year	0.73	1.03
1 year	0.73	1.5
3 years	0.53	1.98
5 years	0.53	2.99
10 years	0.53	3.79

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	31/05/2023
Lucie Larguier DFI	Director of Finance/CFO	-	26/03/2024
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	26/07/2010
Jean-Luc Bélingard BRD	Director/Board Member	76	18/06/2013
Alain Mérieux BRD	Director/Board Member	87	31/12/2006

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-01	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
12-01	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
01/08/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-0.53%	-3.23%	-22.52%	-61.70%	240M
ARGENX SE	+3.23%	+2.93%	+61.50%	+113.87%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+5.05%	+43.44%	+36.75%	43.86B
BIONTECH SE	+3.04%	+6.61%	-13.27%	-18.06%	22.63B
INSMED INCORPORATED	+3.07%	-0.60%	-3.09%	+392.25%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	-0.27%	+12.68%	-37.07%	15.84B
GENMAB A/S	+5.27%	+1.71%	+11.09%	-38.81%	14.83B
EXELIXIS, INC.	+0.65%	-1.04%	+25.60%	+174.70%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+4.13%	+13.12%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	-0.27%	+4.82%	+75.35%	+104.79%	11.56B
Average	+0.88%	-0.11%	+20.39%	+74.08%	21B
Weighted average by Cap.	+1.52%	+0.18%	+31.56%	+90.50%

	2026 *	2027 *
Net sales	7.2M 8.28M 6.62M 6.23M 11.68M 787M 11.81M 78.73M 30.55M 384M 31.08M 30.41M 1.33B	7.2M 8.28M 6.62M 6.23M 11.68M 787M 11.81M 78.73M 30.55M 384M 31.08M 30.41M 1.33B
Net income	-38.2M -43.95M -35.14M -33.05M -61.96M -4.17B -62.64M -418M -162M -2.04B -165M -161M -7.06B	-61.6M -70.87M -56.67M -53.3M -99.91M -6.73B -101M -674M -261M -3.29B -266M -260M -11.38B
Net Debt	-69.2M -79.61M -63.66M -59.88M -112M -7.56B -113M -757M -294M -3.7B -299M -292M -12.79B	-7.7M -8.86M -7.08M -6.66M -12.49M -841M -12.63M -84.2M -32.67M -411M -33.24M -32.52M -1.42B